Other upgrades include easy interface switching and program naming to
improve ease of use
SAN DIEGO--(BUSINESS WIRE)--
ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected
respiratory care devices, today announced key upgrades to its Astral
life support ventilators, including Optional AutoEPAP in iVAPS for U.S.
patients, a high-demand therapy option.
This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180827005110/en/
ResMed's Astral ventilator (Photo: Business Wire)
What is AutoEPAP?
AutoEPAP (automatic expiratory positive airway pressure) automatically
adjusts a patient’s expiratory pressure in response to flow limitations
or obstruction of the upper airway.
AutoEPAP is now available in the United States, and already in use in
other markets. It’s an option when in Astral’s iVAPS (intelligent
Volume-Assured Pressure Support) mode that automatically adapts to a
patient’s changing pressure needs as their respiratory disease
progresses.
Other upgrades
In addition to AutoEPAP, Astral users worldwide can now:
-
Easily change interfaces: Patients can easily change between a
mouthpiece and a full face, nasal or pillows mask from a single limb
circuit.
-
Customize program names: Clinicians can now name programs on a
patient’s Astral device for fast, easy access.
“These significant upgrades make Astral one of the most advanced life
support ventilators on the market,” said Richie McHale, president of
ResMed’s Respiratory Care business. “It’s already proven to stabilize
ventilation in significantly fewer breaths than its leading competitor,1
and today’s innovations offer greater ease of use and even more peace of
mind to patients across a wide range of respiratory diseases than ever
before.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company
with more than 5 million cloud-connected devices for daily remote
patient monitoring, changes lives with every breath. Its award-winning
devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions.
Its 6,000-member team strives to improve patients’ quality of life,
reduce the impact of chronic disease and save healthcare costs in more
than 120 countries. ResMed.com
1 Diesem Ryan. Astral/Trilogy iVAPS/AVAPS Comparison. Valley
Inspired Products 2016; 16011.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180827005110/en/
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
[email protected]
or
For
investors:
Amy Wakeham
+1 858.836.5000
[email protected]
Source: ResMed